Cardiovascular risk assessment (e.g., QRISK3) and management of modifiable risks are important components of care
Risk of bias (quality) assessment Two reviewers (ZJ & JL) independently assessed the quality of the selected studies for risk of bias
Need a daily moisturizing and brightening cream
GLP-1 receptor agonists may be considered when additional treatment goals include weight reduction, improved glycemic control, chronic kidney disease risk reduction, or lowering atherosclerotic cardiovascular risk, particularly in patients with obesity or established Atherosclerotic Cardiovascular Disease (ASCVD) [7, 16, 47]
Patients should also avoid assuming that off-label use is interchangeable with an FDA-approved weight-loss indication
PlexusDx supports precision-focused discussions by helping you explore both clinical markers and genetic predispositions in peptide pathways, enabling a more personalized conversation with your provider about whether GLP-1 aligns with your health goals
